perinatologyРоссийский вестник перинатологии и педиатрииRossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)1027-40652500-2228Ltd. “The National Academy of Pediatric Science and Innovation”10.21508/1027-4065-2025-70-4-5-15perinatology-2225Research ArticleСтатьиИммунотерапия острой лимфобластной лейкемии у детей и подростков: начало новой эпохиImmunotherapy of acute lymphoblastic leukemia in children and adolescents: the beginning of a new erahttps://orcid.org/0000-0002-9300-198XКарачунскийА. И.KarachunskyA. I.

Карачунский Александр Исаакович – д.м.н., проф., директор Института онкологии, радиологии и ядерной медицины; проф. кафедры онкологии, гематологии и лучевой терапии Института материнства и детства 

117198, г.Москва, ул.Саморы Машела, д.1

Moscow

https://orcid.org/0000-0001-9670-3728РумянцеваЮ. В.RumyantsevaYu. V.

Румянцева Юлия Васильевна – д.м.н., доцент, зав. отделом исследования лимфопролиферативных; проф. кафедры онкологии, гематологии и лучевой терапии Института материнства и детства

117198, г.Москва, ул.Саморы Машела, д.1

Moscow

https://orcid.org/0000-0002-7802-8180МансуроваЕ. Г.MansurovaE. G.

Мансурова Екатерина Геннадьевна – к.м.н., доцент кафедры факультетской педиатрии Института материнства идетства

117513 г. Москва, ул. Островитянова, д.1

Moscow

ФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева» Минздрава России; ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава РоссииРоссияDmitry Rogachev National Medical Research Center for Children’s Hematology, Oncology and Immunology; Pirogov Russian National Research Medical UniversityRussian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава РоссииРоссияPirogov Russian National Research Medical UniversityRussian Federation2025280820257045–15Copyright © Ltd. “The National Academy of Pediatric Science and Innovation”, 20252025Ltd. “The National Academy of Pediatric Science and Innovation”Ltd. “The National Academy of Pediatric Science and Innovation”https://www.ped-perinatology.ru/jour/about/submissions#copyrightNoticehttps://www.ped-perinatology.ru/jour/article/view/2225

Острая лимфобластная лейкемия — это злокачественное заболевание крови, поражающее в первую очередь детей и подростков, является самой частой формой детского рака. Традиционно лечение острой лимфобластной лейкемии включает химиотерапию, но в последние годы достижения в иммунотерапии показали значительный потенциал для улучшения результатов и снижения токсичности. В статье рассматривается эволюция лечения острой лимфобластной лейкемии, с особым акцентом на иммунотерапевтические подходы, такие как биспецифические антитела (блинатумомаб), конъюгаты антителлекарств (инотузумаб озогамицин) и терапия Т-клетками с химерными антигенными рецепторами (CAR). Эти иммунологические конструкции показали многообещающие результаты в улучшении показателей выживаемости и минимальной остаточной болезни у пациентов с острой лимфобластной лейкемией. Обсуждаются механизмы действия, клиническое применение и ограничения этих вариантов иммунотерапии, подчеркивая их роль в формировании новой эпохи в лечении острой лимфобластной лейкемии.

Acute lymphoblastic leukemia is a malignant blood cancer primarily affecting children and adolescents. Traditionally, acute lymphoblastic leukemia treatment has relied on chemotherapy, but recent advances in immunotherapy have shown substantial potential for improving outcomes and reducing toxicity. This article explores the evolution of acute lymphoblastic leukemia treatment, with a particular focus on immunotherapeutic approaches such as bispecific antibodies (blinatumomab), antibody-drug conjugates (inotuzumab ozogamicin), and chimeric antigen receptor (CAR) T-cell therapy. These immunologic constructs have demonstrated promising results in improving survival rates and minimal residual disease negativity in acute lymphoblastic leukemia patients. The mechanisms of action, clinical applications, and limitations of these immunotherapies are discussed emphasizing their role in shaping a new era in acute lymphoblastic leukemia management.

детиострая лимфобластная лейкемияиммунотерапиябиспецифические моноклональные антителаконъюгаты антител-лекарствхимерные антигенные рецепторыchildrenacute lymphoblastic leukemiaimmunotherapybispecific antibodiesantibody-drug conjugateschimeric antigen receptorReferencesHunger S.P., Mullighan, C.G. Acute Lymphoblastic Leukemia in Children. N. Engl. J. Med. 2015; 373: 1541–1552. DOI: 10.1056/NEJMra1400972Hunger S.P., Mullighan, C.G. Acute Lymphoblastic Leukemia in Children. N. Engl. J. Med. 2015; 373: 1541–1552. DOI: 10.1056/NEJMra1400972Alaggio R., Amador C., Anagnostopoulos I., Attygalle A.D., Araujo I.B.d.O., et al. The 5th Edition of the World Health Organization Classification of Haemato lymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36: 1720–1748. DOI: 10.1038/s41375–022–01620–2Alaggio R., Amador C., Anagnostopoulos I., Attygalle A.D., Araujo I.B.d.O., et al. The 5th Edition of the World Health Organization Classification of Haemato lymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36: 1720–1748. DOI: 10.1038/s41375–022–01620–2Dong Y., Shi O., Zeng Q., Lu X., Wang W., Li Y., Wang Q. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020; 9: 14. DOI: 10.1186/s40164–020–00170–6Dong Y., Shi O., Zeng Q., Lu X., Wang W., Li Y., Wang Q. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020; 9: 14. DOI: 10.1186/s40164–020–00170–6Aur R.J., Simone J., Hustu H.O., Walters T., Borella L., et al. Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood. 1971; 37(3): 272–281Aur R.J., Simone J., Hustu H.O., Walters T., Borella L., et al. Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood. 1971; 37(3): 272–281Riehm H., Gadner H., Henze G., Kornhuber B., Lampert F., Niethammer D., et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transfus. 1990; 33: 439–450. DOI: 10.1007/978–3–642–74643–7_81Riehm H., Gadner H., Henze G., Kornhuber B., Lampert F., Niethammer D., et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transfus. 1990; 33: 439–450. DOI: 10.1007/978–3–642–74643–7_81Rumyntsev А., Krizhanovskiy О., Maschan А., Karachunskiy А., Samochatova Е. Intensive chemotherapy for acute leukemias (AL) in childhood with BFM protocols: Moscow experices 1990–1992. First successes and failures. Annals of Hematology Suppelement 1992; 64: 806Rumyntsev А., Krizhanovskiy О., Maschan А., Karachunskiy А., Samochatova Е. Intensive chemotherapy for acute leukemias (AL) in childhood with BFM protocols: Moscow experices 1990–1992. First successes and failures. Annals of Hematology Suppelement 1992; 64: 806von Stackelberg A., Karachunskiy A., Kudryashova Ju., Miakova N., Belikova L., Rumiantzev A., et al. Toxicity, supportive care and costs of two chemotherapy protocols for treatment of childhood ALL in Russia: BFM 90m and MB 91. Eur J Cancer. 1999; 35(9): 1349–1355. DOI: 10.1016/s0959–8049(99)00112–4von Stackelberg A., Karachunskiy A., Kudryashova Ju., Miakova N., Belikova L., Rumiantzev A., et al. Toxicity, supportive care and costs of two chemotherapy protocols for treatment of childhood ALL in Russia: BFM 90m and MB 91. Eur J Cancer. 1999; 35(9): 1349–1355. DOI: 10.1016/s0959–8049(99)00112–4Karachunskiy A., Herold R., von Stackelberg A., Miakova N., Timakov A., Henze G., et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia Springer Nature 2008; 22(6): 1144–1153. DOI: 10.1038/leu.2008.63Karachunskiy A., Herold R., von Stackelberg A., Miakova N., Timakov A., Henze G., et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia Springer Nature 2008; 22(6): 1144–1153. DOI: 10.1038/leu.2008.63Schmiegelow K., Attarbaschi A., Barzilai S., Escherich G., Frandsen T.L., Halsey C., et al; Ponte di Legno toxicity working group. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol 2016; 17(6):e231–e239. DOI: 10.1016/S1470–2045(16)30035–3Schmiegelow K., Attarbaschi A., Barzilai S., Escherich G., Frandsen T.L., Halsey C., et al; Ponte di Legno toxicity working group. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol 2016; 17(6):e231–e239. DOI: 10.1016/S1470–2045(16)30035–3Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–497. DOI: 10.1038/256495a0Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–497. DOI: 10.1038/256495a0Aldeghaither D.S., Zahavi D.J., Murray J.C., Fertig E.J., Graham G.T., Zhang Y.W., et al. Mechanism of resistance to antibody targeted immune attack. Cancer Immunol. Res. 2019; 7: 230–243. DOI: 10.1158/2326–6066.CIR-18–0266Aldeghaither D.S., Zahavi D.J., Murray J.C., Fertig E.J., Graham G.T., Zhang Y.W., et al. Mechanism of resistance to antibody targeted immune attack. Cancer Immunol. Res. 2019; 7: 230–243. DOI: 10.1158/2326–6066.CIR-18–0266Thiery J., Keefe D., Boulant S., Boucrot E., Walch M., Martinvalet D., et al. Perforin Pores in the Endosomal Membrane Trigger the Release of Endocytosed Granzyme B into the Cytosol of Target Cells. Nat. Immunol. 2011; 12: 770–777. DOI: 10.1038/ni.2050Thiery J., Keefe D., Boulant S., Boucrot E., Walch M., Martinvalet D., et al. Perforin Pores in the Endosomal Membrane Trigger the Release of Endocytosed Granzyme B into the Cytosol of Target Cells. Nat. Immunol. 2011; 12: 770–777. DOI: 10.1038/ni.2050Queudeville M., Ebinger M. Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review). J Clin Med. 2021; 10(12): 2544. DOI: 10.3390/jcm10122544Queudeville M., Ebinger M. Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review). J Clin Med. 2021; 10(12): 2544. DOI: 10.3390/jcm10122544Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, Zhou X, Li S. Antibody-drug conjugates: Recent advances in linker chemistry. Acta Pharm Sin B. 2021 Dec; 11(12): 3889–3907. DOI: 10.1016/j.apsb.2021.03.042Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, Zhou X, Li S. Antibody-drug conjugates: Recent advances in linker chemistry. Acta Pharm Sin B. 2021 Dec; 11(12): 3889–3907. DOI: 10.1016/j.apsb.2021.03.042Kantarjian H.M., DeAngelo D.J., Stelljes M., Martinelli G., Liedtke M., et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016; 375(8): 740–753. DOI: 10.1056/NEJMoa1509277Kantarjian H.M., DeAngelo D.J., Stelljes M., Martinelli G., Liedtke M., et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016; 375(8): 740–753. DOI: 10.1056/NEJMoa1509277Park J.H., Riviére I., Gonen M., Wang X., Sénéchal B., Curran K.J., et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018 Feb 1; 378(5): 449–459. DOI: 10.1056/NEJMoa1709919Park J.H., Riviére I., Gonen M., Wang X., Sénéchal B., Curran K.J., et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018 Feb 1; 378(5): 449–459. DOI: 10.1056/NEJMoa1709919Del Zotto G., Marcenaro E., Vacca P., Sivori S., Pende D., Della Chiesa M., et al. Markers and function of human NK cells in normal and pathological conditions. Cytometry B Clin Cytom. 2017; 92(2): 100–114. DOI: 10.1002/cyto.b.21508Del Zotto G., Marcenaro E., Vacca P., Sivori S., Pende D., Della Chiesa M., et al. Markers and function of human NK cells in normal and pathological conditions. Cytometry B Clin Cytom. 2017; 92(2): 100–114. DOI: 10.1002/cyto.b.21508Dustin M.L., Long E.O. Cytotoxic immunological synapses. Immunol Rev. 2010; 235(1): 24–34. DOI: 10.1111/j.0105–2896.2010.00904.xDustin M.L., Long E.O. Cytotoxic immunological synapses. Immunol Rev. 2010; 235(1): 24–34. DOI: 10.1111/j.0105–2896.2010.00904.x

The authors declare that there are no conflicts of interest present.